In the second webinar of a two-part series, Marcela Smid, MD, MS, MA, Associate Professor at the University of Utah and member of the Society for Maternal-Fetal Medicine (SMFM), explores the growing impact of emerging substances—fentanyl, kratom, and xylazine—on pregnancy and maternal mental health. 

These substances pose unique risks during the perinatal period, yet remain poorly understood in both research and clinical settings. Dr. Smid discusses what is currently known about their use, effects on pregnancy outcomes, and implications for newborn health. She also addresses the challenges of diagnosis and treatment in the context of substance use disorder and co-occurring mental health conditions. 

This presentation provides evidence-informed insights for healthcare professionals, public health advocates, and anyone working to support pregnant women affected by substance use. Attendees will gain critical knowledge to better recognize, respond to, and care for those impacted by these evolving substance-related concerns.